Todos os estudos
AutorizadoFase I e Fase II (Integrada) - Primeira administração em humanosIntervencionista

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years

This research study, called ARO-DM1, is looking into a new medicine for people living with Type 1 Myotonic Dystrophy. We want to find out if this new medicine is safe for people to take and how well their bodies handle it. Researchers will also study how the medicine affects the disease. This first-stage study involves a small number of people and is focused on understanding side effects and proper dosing. Some participants will receive the new medicine, while others will receive a placebo – a harmless substance that looks like the medicine but has no active ingredients. Participants must be between 18 and 65 years old. This important step helps us learn if ARO-DM1 could be a helpful treatment in the future.

Em resumo

Status
Autorizado
Fase
Fase I e Fase II (Integrada) - Primeira administração em humanos
Patrocinador
Sarepta Therapeutics Inc.
Meta de inscrição
58
Iniciar
29 Jan 2026

Sobre o que é este estudo?

This study is about a new medicine, ARO-DM1, for people who have Type 1 Myotonic Dystrophy. Myotonic Dystrophy Type 1 is a genetic condition that causes muscles to become weak and waste away over time. It can affect many parts of the body.

The main goal of this particular study is to check if ARO-DM1 is safe for people to take. Researchers will be carefully looking for any side effects and how strong these side effects might be. They also want to understand how the medicine moves through the body and how the body gets rid of it. This helps them work out the best dose and how often it should be given. We hope this research will bring us closer to new treatments for this condition.

This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans. It's an important step for new medicines to go through these stages to make sure they are safe and potentially effective before they can be used more widely.

Pontos principais

  • This study is testing a new medicine (ARO-DM1) for Type 1 Myotonic Dystrophy.
  • The main goals are to check the medicine's safety and how the body handles it.
  • Participants will receive either the new medicine or a dummy medicine (placebo).
  • It's an early-stage study, focused on understanding side effects and dosing.
  • You must be an adult, aged 18 to 65, to be considered for participation.

Quem pode ser elegível?

This study is designed for adults. To take part, you need to be aged 18 years or older. There is no upper age limit listed, which means people older than 65 might also be considered, but the current range specified is up to 65 years.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Are you 65 years old or younger?
  3. Have you been diagnosed with Type 1 Myotonic Dystrophy?
  4. Are you able to attend regular appointments and follow study instructions?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will likely have several visits to a clinic or hospital. These visits will involve various checks, such as blood tests, physical examinations, and possibly tests to see how your muscles are working. You will receive either the study medicine, ARO-DM1, or a placebo (a dummy medicine) as an injection. Neither you nor the study team will know which you are receiving. The study involves regular follow-up appointments to monitor your health, any side effects, and how your body is responding to the treatment. The total length of your participation, including the treatment period and follow-up, will be decided by the study doctors.

Riscos e benefícios potenciais

Taking part in a study like this might offer a chance to try a new treatment that isn't available yet, which could potentially help your condition. However, there are also risks, as the medicine is still being tested and could cause unexpected side effects. Some side effects might be uncomfortable or even serious. You will be closely monitored by doctors and nurses throughout the study. Remember, joining is always your choice, and you can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (4)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Espanha
  • —
    Não verificado
    Alemanha
  • —
    Não verificado
    Bélgica
  • —
    Não verificado
    Itália

Perguntas frequentes

What is Type 1 Myotonic Dystrophy?

It's a genetic condition that causes muscles to weaken and waste away over time, affecting movement and other body functions.

O que é um 'placebo'?

A placebo is a substance that looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers compare the effects of the new medicine.

What does 'dose-escalating' mean?

It means that different participants will receive different doses of the medicine, starting with small amounts and gradually increasing, so researchers can find the safest and most effective dose.

Why is this an 'early-stage' study?

This is one of the first times the medicine is being tested in people. It's focused on checking safety and how the body handles the medicine before it moves to larger studies.

Saberei se estou recebendo o medicamento real ou o placebo?

No, during the study, neither you nor the study team will know whether you are receiving the active medicine or the placebo. This is to ensure fair results.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.